MedPath

Comparison of the Effect of Microchip and Density Gradient Methods in Intrauterine Insemination Cycles

Not Applicable
Conditions
Infertility, Male
Infertility Unexplained
Interventions
Other: Gradient-Density Centrifugation
Other: MicroFluidic Sperm Sorting Chips
Registration Number
NCT04144244
Lead Sponsor
Bezmialem Vakif University
Brief Summary

Microfluidic chips are one of the methods of sperm separation to eliminate DNA fragmentation in sperm. It is thought that the separation of sperm by centrifugation in the classical gradient density (Percoll) method used in sperm separation in IVF and IUI cycles leads to the increase of reactive oxygen radicals in sperm and this leads to sperm DNA fragmentation. Studies comparing Percoll and microfluidic chip method in terms of sperm, embryo quality and pregnancy rates are limited. In this context, it is aimed to investigate the effect of Percoll or Microfluidic Chip Technology on the quality of sperms and embryos obtained with these sperms and their pregnancy rates prospectively.

Detailed Description

The increase in infertility rate due to environmental and physiological conditions leads to an increase in the use of assisted reproductive techniques. Isolation of living and morphologically normal live sperm is an integrated procedure in commonly used IVF / ICSI(intracytoplasmic sperm injection) / IUI(intrauterine insemination) procedures. Although current IUI procedures result in a successful pregnancy of around 10-15%, the process can be greatly compromised if the selected sperm is abnormal. Microfluidic chips are one of the recommended sperm separation methods to eliminate DNA fragmentation in sperm. It is thought that the separation of the sperm by centrifugation in the classical gradient density (Percoll) method which is used in the separation of sperm in the IUI cycles, causes the increase of reactive oxygen radicals in sperm and this leads to sperm DNA fragmentation. Studies comparing Percoll and microfluidic chip method in terms of sperm, embryo quality and pregnancy rates are limited. In this context, it is aimed to investigate the effect of Percoll or Microfluidic Chip Technology on the quality of sperms and embryos obtained with these sperms and their pregnancy rates prospectively.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Male
Target Recruitment
176
Inclusion Criteria
  • Apply to the infertility clinic due to unexplained infertility and mild male factor (total motile sperm count >5 million)
  • Volunteer
Exclusion Criteria
  • Inadequate follicle development with medication
  • Embryo does not have the appropriate quality for transfer
  • Tubal pathology
  • Total motile sperm count < 5 million
  • Refuse to participate in research

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
gradient-density centrifugationGradient-Density Centrifugationgradient-density centrifugation technique will be used when preparing sperm of male partner and IUI will be made with separated sperm
MicroFluidic Sperm Sorting ChipsMicroFluidic Sperm Sorting ChipsSperm Sorting microfluidic chips will be used when preparing sperm of male partner and IUI will be made with separated sperm
Primary Outcome Measures
NameTimeMethod
Compare microfluid chip and density-gradient methods in terms of embryo qualityaverage of 6 months

Embryo morphology will be assessed on day 3 using the standard criteria of the number of blastomeres and extent of fragmentation and blastomere asymmetry. Top quality embryos on day 3 will be designated as embryos with 7-8 cells, ≤10% fragmentation, and symmetric blastomeres. Using these criteria, the rate of top quality embryos will be analyzed.

Compare microfluid chip and density-gradient methods in terms of IUI successaverage of 6 months

measure the clinical pregnancy rate by using serum beta-HCG (human chorionic gonadotropin) level

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Bezmialem University

🇹🇷

Istanbul, Turkey

© Copyright 2025. All Rights Reserved by MedPath